AstraZeneca shares rise as cancer treatment demand boosts revenue
UKPulse Money Desk
AstraZeneca has reported a 6% increase in first-half revenues to £23bn, with profits rising 2% to £5bn, driven by strong demand for its cancer treatments.
- AstraZeneca's first-half revenues increased by 6% to £23bn.
- Profits for the first half rose by 2% to £5bn.
- The company attributed the growth to strong sales of specific cancer treatments.
AstraZeneca's shares have risen following strong demand for its cancer treatments, which contributed to a 6% increase in first-half revenues, reaching £23bn. The pharmaceutical giant also reported a 2% rise in profits for the same period, totalling £5bn.
Chief Executive Pascal Soriot highlighted the booming sales of specific cancer treatments as a key factor in the company's financial performance.